Happy to share that @rahelnaef.bsky.social from #IfIS #USZ was at #LIVES2025, the annual congress of the European Society of Intensive Care Medicine (ESICM) in Munich. As part of the Winning Abstract Session, she gave a presentation, presented a poster, and joined an interview on families in ICU.
Stack of JAMA journals showing 'JAMA' in bold letters. Text says 'JAMA at ESICM, AI-Powered Diabetes Prevention, H-1B Visa...JAMA Editors' Summary'. A play button is also visible.
In this podcast, JAMA Deputy Editors Linda Brubaker, MD, and Preeti Malani, MD, MSJ, and Associate Editor Christopher Seymour, MD, MSc, discuss research featured at #LIVES2025, diabetes prevention, and issues impacting the physician pipeline.
Listen now: ja.ma/48WY8lL
Interestingly the @esicm.bsky.social had a Bluesky feed for #Lives2025 but I’m not sure people would have known this if they weren’t there? I found it by accident.
We had so much fun and learnt an awful lot at #LIVES2025 @esicm.bsky.social in my opinion the best ICU conference in the world 🗺️
#PHARMA #LIVES2025 . Looking forward to #LIVES2026
A visual representation of the EVERDAC trial, which assessed whether noninvasive monitoring is noninferior to arterial catheterization in terms of death in patients with shock.
EVERDAC trial: In patients with shock, arterial catheterization is recommended to detect hypotensive episodes, but whether noninvasive blood-pressure monitoring could be a safe alternative is unclear. Research findings are summarized in a new Quick Take video. nej.md/47drZnr
#LIVES2025
OBVI the new #ESICM #LIVES2025 #sepsis trials drop the day before my sepsis lecture 😆 Excited to read/digest/translate for #MHP2025 tomorrow!
To follow this up, here is the end result: curated list of ‘papers I want to read’ from my attendance at #Lives2025 #criticalcare 📟 😀
Abstolutely thrilled to receive the N&AHP Best Abstract award for #PEAiCE study @esicm.bsky.social #LIVES2025. Thank you all involved for the contribution to this important project. @sabrinaeggmann.bsky.social @david-mcwilliams.bsky.social @nydahlpeter.bsky.social
I don't put in A lines to improve mortality. That's what BP, oxygen, Abx, time (and sometimes surgeons) are for. I do it to reduce discomfort. Which I am glad to say this trial supports. #LIVES2025
Another successful @esicm.bsky.social & EuroELSO #ECMO workshop at #LIVES2025 in Munich 🇩🇪 !!
We had 5 sessions over 3 days
🫀VA 🫁 VV #ECLS + ECPR #simulation
🚧 circuit & complications troubleshooting
🚑 ECPR cannulation/initiation
See you at #EuroELSO2026 in Dublin 🇮🇪 & #LIVES2026 in Lisbon 🇵🇹!
✨ And just like that, #LIVES2025 comes to a close!
For a week, Munich became the heart of intensive care!
🌍 Over 5100 participants from 130+ countries came together to 𝗖𝗮𝗿𝗲, 𝗖𝗼𝗻𝗻𝗲𝗰𝘁 & 𝗖𝗵𝗮𝗻𝗴𝗲 — advancing intensive care worldwide!
💫 Thank you all for making #LIVESMunich unforgettable!
#ESICM
🌎At the end of #LIVES2025, we would also like to thank our major sponsors & symposia sponsors for their invaluable support of the organisation and, ultimately, the success of our annual congress year after year!
Thanks for your support!
#ESICM #ESICMCongress #LIVESMunich #IntensiveCare #Sponsors
🎓Throughout #LIVES2025, we continued offering multiple #IntensiveCare educational workshops!
🔹Advanced Critical Care Echocardiography
🔹Airway Management in the Critically ill
🔹ECLS/ECMO (joint with EuroELSO)
🔹General Intensive Care Ultrasound
🤝 Thank you to all participants, faculty & industry!
My take from this trial and the JAMA meta analysis from 2022 is that the marginal benefit of SDD has diminished over the last 2 decades and I am not sure it exists anymore. #LIVES2025
European Society of Intensive Care Medicine Original Article | Oct 29, 2025 | NEJM.org Selective Decontamination of the Digestive Tract during Ventilation in the ICU Figure 2. Subgroup Analysis of In-Hospital Death at 90 Days.
In the SuDDICU trial of patients undergoing mechanical ventilation in the intensive care unit, selective decontamination of the digestive tract did not result in a lower incidence of in-hospital death than standard care alone. Full trial results: nej.md/4nhyeN8
#LIVES2025 | @esicm.bsky.social
Core elements of both differing mortality and knowledge gaps laid out here: #Lives2025 #criticalcare
There’s a nice editorial here www.nejm.org/doi/full/10.... #Lives2025
Mortality at 30 days was 22.6% in the glucocorticoid group and 284 patients and 26.0% in the standard-care group (p= 0.02) #Lives2025 #criticalcare
Paper is free here.
www.nejm.org/doi/full/10....
I’m sitting at a boarding gate on the livestream, but the **rapturous applause** in the room for Lucinde and her team has been really quite striking.
#Lives2025 #criticalcare
Next up is SONIA - a trial of low dose steroids for pneumonia, which sheds needed light on care of pts with pneumonia in resource limited settings. Worth appreaciting differing baseline mortality associated with CAP and hitherto underrepresentation of pts in these settings in research #Lives2025
ESICM reads papers from the JAMA Network on a gradient maroon background. The JAMA Network logo is in the upper right corner, and the ESICM logo is in the upper left corner.
📚 Rationale and Methodological Approach Underlying the Development of the Sequential Organ Failure Assessment (SOFA)–2 Score: A Consensus Statement:
📣 Presented today in the #LIVES2025 Hot Topics session.
➡️ Free to read online:
ja.ma/42ZZZ5B
European Society of Intensive Care Medicine Original Article | Oct 29, 2025 | NEJM.org A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia Figure 2. Cumulative Risk of Death from Any Cause.
In a pragmatic trial conducted in general medical wards with limited diagnostic and therapeutic resources in Kenya, glucocorticoids reduced mortality in patients with community-acquired pneumonia. Full trial results: nej.md/47glh02
#LIVES2025 | @esicm.bsky.social
Clearly I need to read it properly - but I also need to make my way to a boarding gate in Munich Airport, so this is to be continued!
#Lives2025 #criticalcare
The trial is reported as +ve but I am not overwhelmed by the outcome: There were 131 131 wins (48.9%) in the CRT-PHR group vs 112 787 (42.1%) in the usual care group for the hierarchical composite primary outcome, with a win ratio of 1.16 (95% CI, 1.02-1.33; P = .04). #Lives2025 #criticalcare
Flow charts also included information on pulse pressure, diastolic pressure (Tier 1) and MAP, cardiac dysfunction (echo) and dobutamine test (Tier 2) at various points #Lives2025 #criticalcare
It’s using a composite outcome (all-cause mortality, duration of vital support, and length of hospital stay at 28 days as an overall ‘win ratio’)
Patients were Sepsis 3.0 defined with shock <4 hours and every intervention was aimed at normalising CRT (normal CRT halted intervention). #Lives2025
ANDROMEDA-SHOCK-2 is up next…. this looks at personalised phenotype-based, capillary refill time (CRT) targeted resuscitation in early septic shock, comparing to standard resuscitation. It is large (86 centres, 19 countries).
Read it free from JAMA: tinyurl.com/mjcj8s5w
#Lives2025 #criticalcare
JAMA Research Summary: "Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock." The study analyzes 1467 adults with septic shock. CRT-PHR showed 131,131 wins (48.9%) vs. Usual Care with 112,787 wins (42.1%).
📊 Research Summary: Personalized resuscitation targeting capillary refill time modestly improved organ support–free days and composite outcomes in early septic shock, but showed no difference in mortality vs usual care.
#LIVES2025 @esicm.bsky.social
ja.ma/4huvHOa
There is a question on stages about the end of the Swan Ganz era and the implication that ‘God help you if you need one now’ ….. could this be the same? Trialest is clear the trial is about a-line as indicated for MAP only….
#Lives2025 #Criticalcare
